Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease: Volume 15-3

CHF 115.05
Auf Lager
SKU
4QK2FCI64IC
Stock 1 Verfügbar
Geliefert zwischen Do., 13.11.2025 und Fr., 14.11.2025

Details

Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.

Zusammenfassung
Hepatitis C Virus is a quickly evolving area within hepatology owing to various medical therapies. This title includes review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors.

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09781455711079
    • Sprache Englisch
    • Genre Medical Books
    • Größe H229mm x B152mm
    • Jahr 2011
    • EAN 9781455711079
    • Format Fester Einband
    • ISBN 978-1-4557-1107-9
    • Veröffentlichung 22.12.2011
    • Titel Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease: Volume 15-3
    • Autor Poordad Fred
    • Gewicht 460g
    • Herausgeber SAUNDERS W B CO
    • Anzahl Seiten 1

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470